Epitalon vs SS-31
Two 'anti-aging peptides' with almost opposite evidence problems — one built on decades-old, unreplicated Russian research, the other with a real (if narrow) FDA approval its marketing rarely mentions.
Epitalon
Epithalon
Marketed for telomerase activation and life extension, but the supporting science is old, small, and almost entirely from one Russian lab — and largely unreplicated.
Full Epitalon evidence reviewSS-31
Elamipretide
A cardiolipin-binding peptide with a mostly disappointing trial history; elamipretide won a narrow, confirmation-pending accelerated FDA approval for Barth syndrome — not for the anti-aging use it's sold for.
Full SS-31 evidence reviewSide by side
| Epitalon | SS-31 | |
|---|---|---|
| Marketed for | Telomerase activation, life extension | Mitochondrial function, longevity |
| Evidence grade | Clinical data | Clinical data |
| Family | Mitochondrial / longevity | Mitochondrial / longevity |
| Regulatory status | Not FDA-approved | FDA-approved |
| How it's obtained | Research-only | Rx product |
| Key human source | Korkushko, Bull Exp Biol Med 2011 | Elamipretide (Barth), Genet Med 2024 |
marks a row where the two differ. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
Our verdict
Epitalon is marketed for telomerase activation and life extension, but nearly all the supporting science is old, small, and from one Russian lab, largely unreplicated elsewhere. SS-31 (elamipretide) has the opposite shape: a mostly disappointing broader trial history, but a genuine, narrow, confirmation-pending FDA accelerated approval for Barth syndrome — a real regulatory milestone that has nothing to do with the general anti-aging use it's sold for.
Epitalon fits if
You're reading about telomerase-activation theory specifically, understanding the evidence base hasn't been independently replicated outside one research group.
SS-31 fits if
You want the compound with an actual FDA milestone behind it, understanding that milestone applies to one rare genetic disease, not general aging.